| Literature DB >> 27557147 |
Jin Li1, Ying Wang1,2, Lei Wang1, Xuefeng Dai2, Wang Cong1, Weixing Feng1, Chengzhen Xu1, Yulin Deng1, Yue Wang3, Todd C Skaar4, Hong Liang5,6, Yunlong Liu7,8,9.
Abstract
BACKGROUND: In combination with gene expression profiles, the protein interaction network (PIN) constructs a dynamic network that includes multiple functional modules. Previous studies have demonstrated that rifampin can influence drug metabolism by regulating drug-metabolizing enzymes, transporters, and microRNAs (miRNAs). Rifampin induces gene expression, at least in part, by activating the pregnane X receptor (PXR), which induces gene expression; however, the impact of rifampin on global gene regulation has not been examined under the molecular network frameworks.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27557147 PMCID: PMC5001204 DOI: 10.1186/s12864-016-2909-6
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1The hierarchical chart of identification of rifampin-regulated functional modules and related miRNAs
Fig. 2The workflow of the RrPIN. Color is according to the fold change where red denotes upregulated and green denotes downregulated
Fig. 3The functional modules of RrPIN. a The maximally functional module of PPI network. Color is according to the fold change where red denotes upregulated and green denotes downregulated. The shape of the nodes depicts the aggregate score: circles indicate a negative score, rectangles denotes a positive score. b, c, d, e and f are the five functional modules of RrPIN. The regulatory relationships are denoted by colours in which red indicates upregulated genes, and green indicates downregulated. As well, the depth of the colour explains the size of fold change
Table of top 20 GO terms and top 10 KEGG terms for the genes of functional modules
| Category | Term | Count | Percent |
| Benjiamini |
|---|---|---|---|---|---|
| GOTERM_BP_FAT | regulation of apoptosis | 19 | 22.6 | 5.10E-07 | 7.30E-04 |
| GOTERM_BP_FAT | regulation of programme cell death | 19 | 22.6 | 5.90E-07 | 4.20E-04 |
| GOTERM_BP_FAT | regulation of cell death | 19 | 22.6 | 6.20E-07 | 3.00E-04 |
| GOTERM_BP_FAT | negative regulation of apoptosis | 13 | 15.5 | 7.90E-07 | 2.80E-04 |
| GOTERM_BP_FAT | negative regulation of programmed cell death | 13 | 15.5 | 9.10E-07 | 2.60E-04 |
| GOTERM_BP_FAT | negative regulation of cell death | 13 | 15.5 | 9.40E-07 | 2.20E-04 |
| GOTERM_BP_FAT | membrane organization | 13 | 15.5 | 1.70E-06 | 3.50E-04 |
| GOTERM_BP_FAT | vesicle-mediated transport | 15 | 17.9 | 4.50E-06 | 8.10E-04 |
| GOTERM_BP_FAT | membrane invagination | 10 | 11.9 | 4.70E-06 | 7.40E-04 |
| GOTERM_BP_FAT | endocytosis | 10 | 11.9 | 4.70E-06 | 7.40E-04 |
| GOTERM_BP_FAT | response to hypoxia | 8 | 9.5 | 1.20E-05 | 1.70E-03 |
| GOTERM_BP_FAT | response to oxygen levels | 8 | 9.5 | 1.60E-05 | 2.10E-03 |
| GOTERM_BP_FAT | response to inorganic substance | 9 | 10.7 | 2.30E-05 | 2.70E-03 |
| GOTERM_BP_FAT | anti-apoptosis | 9 | 10.7 | 2.40E-05 | 2.60E-03 |
| GOTERM_BP_FAT | positive regulation of multicellular organismal process | 9 | 10.7 | 7.90E-05 | 8.00E-03 |
| GOTERM_BP_FAT | drug metabolic process | 4 | 4.8 | 9.80E-05 | 9.20E-03 |
| GOTERM_BP_FAT | response to metal ion | 7 | 8.3 | 9.80E-05 | 8.70E-03 |
| GOTERM_BP_FAT | phagocytosis | 5 | 6 | 1.60E-04 | 1.40E-02 |
| GOTERM_BP_FAT | response to organic substance | 14 | 16.7 | 2.20E-04 | 1.80E-02 |
| GOTERM_BP_FAT | regulation of tube size | 5 | 6 | 2.40E-04 | 1.80E-02 |
| KEGG_PATHWAY | Metabolism of xenobiotics by cytochrome P450 | 6 | 7.1 | 2.00E-04 | 1.70E-02 |
| KEGG_PATHWAY | Retinol metabolism | 5 | 6 | 1.40E-03 | 6.00E-02 |
| KEGG_PATHWAY | Drug metabolism | 5 | 6 | 2.40E-03 | 6.70E-02 |
| KEGG_PATHWAY | Linoleic acid metabolism | 3 | 3.6 | 2.70E-02 | 4.50E-01 |
| KEGG_PATHWAY | Pathways in cancer | 8 | 9.5 | 2.90E-02 | 4.00E-01 |
| KEGG_PATHWAY | Focal adhesion | 6 | 7.1 | 3.70E-02 | 4.10E-01 |
| KEGG_PATHWAY | Porphyrin and chlorophyll metabolism | 3 | 3.6 | 3.70E-02 | 3.70E-01 |
| KEGG_PATHWAY | Small cell lung cancer | 4 | 4.8 | 4.20E-02 | 3.70E-01 |
| KEGG_PATHWAY | ECM-receptor interaction | 4 | 4.8 | 4.20E-02 | 3.70E-01 |
| KEGG_PATHWAY | TGF-beta signaling pathway | 4 | 4.8 | 4.60E-02 | 3.60E-01 |
Enrichment analysis of the maximally functional module in rifampin
| DAVID (Term) | Genes |
|
|---|---|---|
| GO: Response to drug | ABCB1,UGT1A4,CAV1,CAV2 | 3.6E-2 |
| KEGG: Metabolism of xenobiotics by cytochrome P450 | UGT1A4,ADH6,CYP1A1,CYP2C19,CYP2C9,CYP2E1 | 2.0E-4 |
| KEGG: Retinol metabolism | UGT1A4,ADH6,CYP1A1,CYP2C19,CYP2C9 | 1.4E-3 |
| KEGG: Drug metabolism | UGT1A4,ADH6, CYP2C19,CYP2C9,CYP2E1 | 2.4E-3 |
| KEGG: Linoleic acid metabolism | CYP2C19,CYP2C9,CYP2E1 | 2.7E-2 |
| KEGG: Pathways in cancer | CEBPA,CREBBP,SMAD3,TRAF2,BIRC3,EGLN2,FN1,IKBKG | 2.9E-2 |
| Focal adhesion | BIRC3,CAV1,CAV2,FN1,ITGA1,THBS1 | 3.7E-2 |
Fig. 4The pathway relative abundance of maximally functional module’s genes and all SDGs on the associated seven functional enrichment terms
Fig. 5The RrPIN extension network of 19 genes and associated 7 functions
The significant differentially expressed miRNAs
| miRNA |
| miRNA |
|
|---|---|---|---|
| Upregulated | Upregulated | ||
| miR-886-3p | 0.0002 | miR-660 | 0.0297 |
| miR-766 | 0.0075 | miR-638 | 0.0302 |
| miR-92a | 0.0169 | miR-25 | 0.0338 |
| miR-107 | 0.0177 | miR-616 | 0.0446 |
| miR-30d# | 0.0195 | miR-576-3p | 0.0453 |
| miR-335 | 0.0241 | miR-218 | 0.0499 |
| Downregulated | Downregulated | ||
| miR-186 | 0.0018 | miR-320 | 0.0376 |
| miR-361 | 0.0111 | miR-202 | 0.0396 |
| miR-95 | 0.0219 | miR-200b# | 0.0426 |
| miR-345 | 0.0239 | let-7 g | 0.0435 |
The miRNA-regulated PIN which constructed by the genes of functional modules
| Gene list | logFC | miRNA |
| Fold change |
|---|---|---|---|---|
| CYP2E1 | −1.4341 | miR-335 | 0.0242 | 1.3300 |
| CAV1 | −0.8518 | miR-34b | 0.1753 | 185.3764 |
| miR-886-3p | 0.0001 | 1.5645 | ||
| miR-218 | 0.0499 | 1.9012 | ||
| miR-576-3p | 0.0453 | 2.1916 | ||
| CAV2 | −0.5386 | miR-200c | 0.0913 | 4.8313 |
| miR-576-3p | 0.0453 | 2.1916 | ||
| CEBPA | 0.5812 | miR-186 | 0.0017 | 0.8356 |
| CREBBP | 0.3821 | miR-186 | 0.0017 | 0.8356 |
| miR-95 | 0.0216 | 0.6320 | ||
| miR-769 | 0.1249 | 0.8388 | ||
| EGLN2 | 0.4574 | miR-202 | 0.0396 | 0.5988 |
| let-7 g | 0.0435 | 0.8402 | ||
| ITGA1 | −0.3754 | miR-616 | 0.0446 | 1.3337 |
| miR-660 | 0.0297 | 1.2642 | ||
| miR-576-3p | 0.0453 | 2.1916 | ||
| miR-335 | 0.0242 | 1.3300 | ||
| THBS1 | −0.3951 | miR-886-3p | 0.0001 | 1.5645 |
| miR-335 | 0.0242 | 1.3300 | ||
| miR-616 | 0.0446 | 1.3337 | ||
| miR-92a | 0.0169 | 1.1319 |
Fig. 6The miRNA-regulated PIN which is constructed by the genes of functional modules
The potential functions of miRNAs
| DAVID (Term) | miRNA |
|---|---|
| GO: Response to drug | miR-34b, miR-886-3p, miR-218, miR-576-3p, miR-200c |
| KEGG: Metabolism of xenobiotics by cytochrome P450 | miR-335 |
| KEGG: Drug metabolism | miR-335 |
| KEGG: Linoleic acid metabolism | miR-335 |
| KEGG: Pathways in cancer | miR-186, miR-95, miR-769 |
| Focal adhesion | miR-34b, miR-886-3p, miR-218, miR-576-3p, miR-200c, miR-616, miR-660, miR-335, miR-92a |